Zacks Research assessed
Bio-Rad Laboratories, Inc.'s Q2 2024
earnings, while the company's stock, though gaining, lagged behind the market. Notably,
Bio-Rad's shares were
upgraded to 'Buy' by StockNews.com, making the current share price of US$325 intriguing for potential investors. Despite
Forex worries, the company's
product launches are proving beneficial. Major financial institutions, including Artisan Partners and Norges Bank, recently
purchased Bio-Rad shares. Unfortunately, investors who acquired shares three years ago are currently at a loss, and the stock has suffered a 14% decrease this week. However, financial firms are maintaining holdings in Bio-Rad, signifying confidence. The company's balance sheet is considered healthy while their Q1 2024 earnings surpassed estimates. However, Bio-Rad also faces competition and softness within BioPharma, affecting its performance. Oncocyte's
partnership with Bio-Rad caused a 90% surge for Oncocyte post-market. Bio-Rad's first quarter 2024 earnings show a substantial increase from the same period in the previous year. Even with some ups and downs, Wall Street Analysts predict a 28.56% upside is possible for Bio-Rad, making it worth a second look for investors.
Bio-Rad Laboratories Stocks News Analytics from Mon, 09 Nov 2020 08:00:00 GMT to Thu, 30 May 2024 09:44:38 GMT -
Rating 0
- Innovation -3
- Information 7
- Rumor 2
